Eagle Pharms

EGRX NASDAQ
53.85
-0.81
-1.48%
After Hours: 53.85 0 0.00% 18:41 07/19 EDT
Open
54.62
Prev Close
54.66
High
54.70
Low
52.74
Volume
139.77K
Avg Vol (3M)
172.04K
52 Week High
85.12
52 Week Low
36.03
% Turnover
1.00%
Market Cap
750.10M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Eagle Pharms EGRX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
MORE >

Recently

Name
Price
%Change